Kirsten Axelsen
Oct. 12, 2023
Coverage with Evidence Development
Kirsten Axelsen, Senior Policy Advisor with global law firm DLA Piper, explains what Coverage with Evidence Development is and how it restricts patients access; the manufacturers of all 10 of the first drugs announced for Me…
None
Sept. 26, 2023
CMS Drug Price Negotiations
Kirsten Axelsen, Senior Policy Advisor at DLA Piper, says some of the fallout from CMS announcing price controls is already happening; the E&C Oversight and Investigations Subcommittee held a hearing on the IRA’s price-setti…
None